RAPID MICRO BIOSYSTEMS, INC.
About RAPID MICRO BIOSYSTEMS, INC.
Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $33.6M
- Net income
- -$47.1M
- Total assets
- $74.9M
- Market cap
- $99.1M
- Operating margin
- -141.1%
- Net margin
- -140.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $33.6M
- Operating expenses
- $81.0M
- Operating income
- -$47.4M
- Income tax
- $40.0K
- Net income
- -$47.1M
- EPS (basic)
- $-1.05
- EPS (diluted)
- $-1.05
Balance sheet
- Total assets
- $74.9M
- Current assets
- $61.2M
- Total liabilities
- $41.6M
- Current liabilities
- $18.5M
- Shareholders’ equity
- $33.2M
Cash flow
- Operating cash flow
- -$31.1M
- Investing cash flow
- $14.3M
- Financing cash flow
- $19.8M
- Net cash flow
- $3.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $99.1M
- EPS (diluted)
- $-1.05
- Shares outstanding
- 49.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 15, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $47.1M in FY2025.
- Revenue grew 45% from FY2021 to FY2025.
- Trading 57% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review RAPID MICRO BIOSYSTEMS, INC..
Write a review
News about RAPID MICRO BIOSYSTEMS, INC.
News & sentiment via Polygon.io
